BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children

Area of Science:

• Oncology
• Cell Biology
• Genetics

Background:

• Langerhans cell histiocytosis (LCH) is a rare proliferative disorder of dendritic cells.
• Recurrent mutations in BRAF (BRAFV600E) and MAP2K1 have been identified in LCH.
• Understanding the clinical and differentiation implications of these mutations is crucial for LCH management.

Purpose of the Study:

• To investigate the relationship between BRAFV600E and MAP2K1 mutations, clinical features, and cellular differentiation in LCH.
• To determine the prevalence of these mutations in a cohort of LCH patients.
• To explore the association between these mutations and the RAS/RAF/MEK/ERK signaling pathway.

Main Methods:

• Sanger sequencing was used to detect BRAFV600E and MAP2K1 mutations in 97 LCH cases.
• Immunohistochemistry was employed to assess cell differentiation markers (CD14, CD83, CD86) and pERK expression.
• Statistical analysis was performed to correlate mutation status with clinical findings and differentiation markers.

Main Results:

• BRAFV600E and MAP2K1 mutations were found in 32% and 17.5% of LCH cases, respectively, and occurred mutually exclusively.
• These mutations were significantly more frequent in children than adults and BRAF mutations correlated with relapse.
• Mutated LCH cells expressed CD14 but lacked CD83/CD86, indicating an immature phenotype, and showed increased pERK expression compared to wild-type LCH.

Conclusions:

• BRAFV600E and MAP2K1 mutations are prevalent in LCH, particularly in children, and are associated with an immature dendritic cell phenotype.
• The RAS/RAF/MEK/ERK pathway activation, indicated by pERK expression, is linked to these mutations.
• These findings highlight the importance of the RAS/RAF/MEK/ERK pathway in LCH pathogenesis, especially in pediatric cases.